Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2

Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2

From HCPLive Podcasts by HCPLive.com

May 28, 2026 · 28 min

About this episode

The episode discusses the potential role of GLP-1 receptor agonists in treating inflammatory arthritides based on early data.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, turn from osteoarthritis to the inflammatory arthritides — examining what early data in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and lupus can and cannot yet tell us about the role of GLP-1 receptor agonists in disease modification. “Everyone is talking about [GLP-1 RAs] and what it can do for our patients. Much more evidence is needed to be much more better understanding about increasing effects beyond weight loss is needed. And I think that evidence will be just coming out very rapidly, year by year… but I think this is not the case where we're going to wait for strong evidence, good quality RCT data before we start to start to use them,” Buss said.

People in this episode

Hosts: Jack Arnold, Rihards Buss

Topics covered

  • GLP-1 receptor agonists
  • rheumatoid arthritis
  • psoriatic arthritis
  • lupus
  • disease modification
  • inflammatory arthritides

Keywords

  • GLP-1 receptor agonists
  • rheumatoid arthritis
  • psoriatic arthritis
  • lupus
  • disease modification
  • inflammatory arthritides
  • weight loss

Mentioned in this episode

Organizations: University of Leeds, Freeman Hospital

Products: GLP-1 receptor agonists

Places: Newcastle

More episodes of HCPLive Podcasts

Explore listener stats, chart rankings, contacts and more on the HCPLive Podcasts podcast page.